Being able to run a rapid strep test doesn’t automatically mean you can prescribe based on the result — testing authority and prescribing authority are governed by different rules, and most states grant the first more broadly than the second. If you’re building a testing service, the CLIA waiver and your state’s scope-of-practice statute matter as much as the test kit itself.
Testing authority vs. prescribing authority
These are two separate legal questions that get conflated constantly. Point-of-care testing authority is about whether a pharmacist can legally administer a specific test and interpret the result. Prescribing authority is about whether the pharmacist can then act on that result by initiating treatment without routing back through a physician. A state can — and many do — allow broad testing authority while restricting the prescribing piece to a collaborative practice agreement or standing order. For the prescribing side specifically, see our companion post on test-and-treat authority by state.
CLIA waiver: the federal layer underneath state law
Before any state-law question matters, the test itself has to be CLIA-waived (or the pharmacy has to hold a higher-complexity CLIA certificate, which is uncommon in community pharmacy). CLIA waiver is a federal quality-standards classification under the Clinical Laboratory Improvement Amendments — it’s not pharmacy-specific, and it applies to any facility running the test, not just pharmacies. Most of the rapid tests pharmacies use (flu, strep, COVID-19 antigen, glucose, A1C, cholesterol, INR) are CLIA-waived, which is precisely why they’re the tests pharmacies commonly offer. Facilities need a CLIA Certificate of Waiver on file before running any waived test, and state health departments or CMS enforce that separately from the board of pharmacy’s scope-of-practice rules.
What pharmacists can commonly test for
Availability still varies by state, but the following are the tests most frequently authorized for pharmacist administration:
- Influenza A/B — rapid antigen testing, widely authorized
- Group A Streptococcus — rapid strep testing, widely authorized
- COVID-19 — antigen testing, broadly authorized following pandemic-era scope expansions in most states
- A1C and blood glucose — long-standing point-of-care tests, generally allowed everywhere as part of routine collaborative practice agreement or wellness-screening services
- Cholesterol/lipid panels — commonly allowed as a screening service
- INR (for warfarin monitoring) — widely used in anticoagulation management programs
- HIV — a growing number of states allow pharmacist-administered rapid HIV testing, often tied to broader public-health and harm-reduction initiatives alongside naloxone dispensing and syringe services programs
- Hepatitis C — expanding but still less uniformly authorized than flu/strep/COVID
How states structure the authority
Training requirements
Even in states with broad statutory testing authority, most require the individual pharmacist to complete test-specific training before administering it — commonly an ACPE-accredited certificate program covering the specific disease state, proper specimen collection, quality control procedures, and result interpretation. CLIA waiver itself doesn’t require a formal certification for the operator, but state board rules frequently layer their own training or continuing education requirement on top of the federal waiver, so check both.
Where this connects to immunizations
Point-of-care testing programs often sit alongside immunization services in practice — a patient testing positive for flu may also be a candidate for a same-visit vaccination consult, and testing infrastructure (private consultation space, documentation systems, physician notification workflows) overlaps significantly with what’s needed for immunization authority programs. If you’re building out either service, it’s efficient to plan them together rather than as separate initiatives.
Building a testing program: practical checklist
- Confirm your state board’s current list of tests pharmacists may administer — this list is amended more often than most other scope-of-practice provisions
- Obtain the CLIA Certificate of Waiver for the pharmacy location before offering any test
- Complete state-required (or ACPE-recommended) training for each specific test you plan to offer
- Separately confirm whether prescribing based on results requires a CPA, standing order, or is covered by statutory authority — don’t assume testing authority includes treatment authority
- Establish a documentation and physician-notification workflow, which many states require regardless of the testing/prescribing distinction
CLIA-waived test lists, state scope-of-practice statutes, and training requirements all change periodically — verify current requirements with your state board of pharmacy and CMS before launching or expanding a testing service.
Track testing and prescribing authority together
RxByState tracks point-of-care testing authority, CLIA-related state requirements, and test-and-treat prescribing rules for all 50 states in one dashboard. Start a free 14-day trial →